Trials / Recruiting
RecruitingNCT06637371
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 691 | Subcutaneous (SC) injection |
| DRUG | Placebo | SC injection |
Timeline
- Start date
- 2024-10-16
- Primary completion
- 2027-06-07
- Completion
- 2027-06-07
- First posted
- 2024-10-15
- Last updated
- 2026-04-09
Locations
21 sites across 5 countries: United States, Australia, Belgium, Canada, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06637371. Inclusion in this directory is not an endorsement.